Quarterly report pursuant to Section 13 or 15(d)

Other current assets (Tables)

v3.24.1.1.u2
Other current assets (Tables)
3 Months Ended
Mar. 31, 2024
Other current assets  
Summary of other current assets

March 31, 

December 31, 

    

2024

2023

Research and development credits receivable

 

$

18,697

$

46,098

Prepayments

 

9,854

9,954

Clinical materials

 

1,668

1,329

VAT receivable

1,791

Other current assets

 

2,837

2,412

$

34,847

$

59,793